Latest filings (excl ownership)
PRE 14A
Preliminary proxy
12 Apr 24
8-K
Entry into a Material Definitive Agreement
22 Mar 24
424B5
Prospectus supplement for primary offering
22 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 24
S-8
Registration of securities for employees
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
19 Mar 24
8-K
Adicet Bio, Inc. Announces Proposed Public Offering
24 Jan 24
424B5
Prospectus supplement for primary offering
24 Jan 24
424B5
Prospectus supplement for primary offering
22 Jan 24
8-K
Regulation FD Disclosure
16 Jan 24
8-K
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024
4 Jan 24
8-K
Departure of Directors or Certain Officers
13 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
8 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 23
S-8
Registration of securities for employees
9 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates
9 Aug 23
8-K
Adicet Announces Appointment of Katie Peng to the Board of Directors
11 Jul 23
8-K
Regulation FD Disclosure
26 Jun 23
8-K
Entry into a Material Definitive Agreement
5 Jun 23
8-K
Departure of Directors or Certain Officers
2 Jun 23
8-K
Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
18 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates
9 May 23
ARS
2022 FY
Annual report to shareholders
18 Apr 23
DEF 14A
Definitive proxy
18 Apr 23
DEFA14A
Additional proxy soliciting materials
18 Apr 23
S-8
Registration of securities for employees
15 Mar 23
10-K
2022 FY
Annual report
15 Mar 23
8-K
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
15 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Regulation FD Disclosure
12 Dec 22
8-K
Entry into a Material Definitive Agreement
8 Dec 22
8-K
Regulation FD Disclosure
10 Nov 22
424B5
Prospectus supplement for primary offering
8 Nov 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
8 Nov 22
8-K
Regulation FD Disclosure
3 Nov 22
Latest ownership filings
SC 13D/A
ORBIMED ADVISORS LLC
21 Mar 24
SC 13G
MILLENNIUM MANAGEMENT LLC
27 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G
MORGAN STANLEY
12 Feb 24
SC 13G/A
BlackRock Inc.
7 Feb 24
SC 13D/A
Carlyle Group Inc.
7 Feb 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
5 Feb 24
SC 13G/A
Cowen Financial Products LLC
2 Feb 24
SC 13G/A
BlackRock Inc.
31 Jan 24
SC 13D/A
ORBIMED ADVISORS LLC
29 Jan 24
4
Change in insider ownership
26 Jan 24
4
CARL L GORDON
26 Jan 24
4
Francesco Galimi
26 Jan 24
4
Blake Aftab
26 Jan 24
4
Don Healey
26 Jan 24
4
Brian Nicholas Harvey
26 Jan 24
4
Chen Schor
26 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
SC 13G
COMMODORE CAPITAL LP
19 Jan 24
4
Blake Aftab
16 Oct 23
4
Francesco Galimi
3 Oct 23
4
Don Healey
3 Oct 23
4
Brian Nicholas Harvey
3 Oct 23
4
Chen Schor
2 Oct 23
144
Notice of proposed sale of securities
29 Sep 23
4
Chen Schor
16 Aug 23
4
Francesco Galimi
16 Aug 23
4
Blake Aftab
16 Aug 23
4
Brian Nicholas Harvey
16 Aug 23
4
Don Healey
16 Aug 23
4
CARL L GORDON
16 Aug 23
4
Bastiano Sanna
16 Aug 23
4
Andrew Sinclair
16 Aug 23
4
Michael Kauffman
16 Aug 23
4
STEVE DUBIN
16 Aug 23
4
Aya Jakobovits
16 Aug 23
4
Jeffrey Chodakewitz
16 Aug 23
4
Katie Peng
16 Aug 23